Compare SII & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SII | SYRE |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2011 | 2015 |
| Metric | SII | SYRE |
|---|---|---|
| Price | $147.67 | $39.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $132.00 | $55.57 |
| AVG Volume (30 Days) | 212.7K | ★ 693.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.22 | N/A |
| Revenue Next Year | $11.39 | N/A |
| P/E Ratio | $63.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.33 | $10.91 |
| 52 Week High | $169.63 | $45.76 |
| Indicator | SII | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 50.97 | 54.58 |
| Support Level | $79.37 | $38.36 |
| Resistance Level | $167.47 | $45.76 |
| Average True Range (ATR) | 7.95 | 1.93 |
| MACD | -1.76 | -0.43 |
| Stochastic Oscillator | 6.12 | 28.37 |
Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.